Silver Book Fact

It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall the study finds that the value of increased longevity through these potential innovations will greatly exceed the rising costs of health care.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • A recent study showed that memantine, a medicine approved to treat moderate-to-severe Alzheimer’s, significantly slows cognitive decline and reduces the need for caregiving by 45.8 hours per month.  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…